![Patrick Yeramian](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Yeramian
Corporate Officer/Principal chez
Dlx Therapeutics L L C
Profil
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Postes actifs de Patrick Yeramian
| Sociétés | Poste | Début |
|---|---|---|
Dlx Therapeutics L L C | Corporate Officer/Principal | 01/01/2018 |
Anciens postes connus de Patrick Yeramian
| Sociétés | Poste | Fin |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 28/11/2023 |
| BIOVIE INC. | Directeur Technique/Scientifique/R&D | 01/11/2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Directeur Technique/Scientifique/R&D | 01/03/2019 |
| MARKER THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
Tapimmune, Inc. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
Formation de Patrick Yeramian
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
15
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Develops and researches immunological products | Health Technology |
Marker Therapeutics, Inc.
 Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
BioVie, Inc.
 BioVie, Inc. BiotechnologyHealth Technology Develops drug therapies for chronic debilitating conditions | Health Technology |
Université de Paris XI Paris Sud
 Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Universite Paris Est Creteil Val De Marne
 Universite Paris Est Creteil Val De Marne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
G.D. Searle LLC | |
Rutgers Business School
 Rutgers Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Provides research services | Commercial Services |
Amylyx Pharmaceuticals, Inc.
 Amylyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products to cure neurodegenerative diseases | Health Technology |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel and receptor antagonist-based therapeutics for AKI diagnostic tests | Commercial Services |
Dlx Therapeutics L L C | |
Tapimmune, Inc. |
